Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ocugen, Inc.HSGX · Entity 5550 | Director | June 15, 2018 | June 19, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ocugen, Inc.
Report date June 15, 2018 · Filed June 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.97 · Expires 2028-06-14 | Direct | 25,000 |
Reported balance
After 2018-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-15 · Grant · Acquired 25,000 · Balance 25,000 F1: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ENTELLUS MEDICAL INC
Report date February 28, 2018 · Filed March 01, 2018
Section 16 reporting ended · disclosed 2018-03-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 1
1 source rowRow 1 · 2018-02-28 · Disposition to issuer · Disposed 5,350 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.36 · Expires 2024-12-16 | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-28 · Disposition to issuer · Disposed 13,750 · Balance 0 F2: This option, which provided for vesting in quarterly installments over 36 months commencing on December 1, 2014, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.26 · Expires 2026-06-14 | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-28 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: This option, which provided for vesting in full on the earlier of June 14, 2017 and the date of the annual stockholder meeting following June 14, 2016, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.38 · Expires 2027-06-13 | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-28 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: This option, which provided for vesting in full on the earlier of June 13, 2018 and the date of the annual stockholder meeting following June 13, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share.
F2: This option, which provided for vesting in quarterly installments over 36 months commencing on December 1, 2014, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.
F3: This option, which provided for vesting in full on the earlier of June 14, 2017 and the date of the annual stockholder meeting following June 14, 2016, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.
F4: This option, which provided for vesting in full on the earlier of June 13, 2018 and the date of the annual stockholder meeting following June 13, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2018 Filed Jun 19, 2018 16:41 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0000899243-18-017187 · doc4.xml · derivative · entry 1 Baltzell Joshua J · CIK 0001418439 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 14:34 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | $10.62 Strike: $13.38 | $53,100.00 |
DisclosureSEC source: 0001235802-18-000023 · primary_doc.xml · derivative · entry 4 Baltzell Joshua J · CIK 0001418439 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2027-06-13 F4 · derivative.exercise_date: This option, which provided for vesting in full on the earlier of June 13, 2018 and the date of the annual stockholder meeting following June 13, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 14:34 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | $5.74 Strike: $18.26 | $57,400.00 |
DisclosureSEC source: 0001235802-18-000023 · primary_doc.xml · derivative · entry 3 Baltzell Joshua J · CIK 0001418439 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-06-14 F3 · derivative.exercise_date: This option, which provided for vesting in full on the earlier of June 14, 2017 and the date of the annual stockholder meeting following June 14, 2016, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 14:34 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | Disposition to issuerStock Option (right to buy) · Derivative | 13,750 | $12.64 Strike: $11.36 | $173,800.00 |
DisclosureSEC source: 0001235802-18-000023 · primary_doc.xml · derivative · entry 2 Baltzell Joshua J · CIK 0001418439 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,750 shares Expires 2024-12-16 F2 · derivative.exercise_date: This option, which provided for vesting in quarterly installments over 36 months commencing on December 1, 2014, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 14:34 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | Disposition to issuerCommon Stock, $0.001 par value | 5,350 | $24.00 | $128,400.00 |
DisclosureSEC source: 0001235802-18-000023 · primary_doc.xml · nonDerivative · entry 1 Baltzell Joshua J · CIK 0001418439 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 17:00 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000899243-17-016392 · doc4.xml · derivative · entry 1 Baltzell Joshua J · CIK 0001418439 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 13, 2017. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 16:10 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $13.38 | $0.00 |
DisclosureSEC source: 0001235802-17-000080 · primary_doc.xml · derivative · entry 2 Baltzell Joshua J · CIK 0001418439 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-13 F2 · derivative.exercise_date: This option vests in full on the earlier to occur of June 13, 2018 and the date of the Company's annual meeting of stockholders immediately following June 13, 2017, subject to the Reporting Person's continued service with the Company through the applicable vesting date. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 16:10 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | GrantCommon Stock, $0.001 par value | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-17-000080 · primary_doc.xml · nonDerivative · entry 1 Baltzell Joshua J · CIK 0001418439 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,350 F1 · shares: Includes 2,500 shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Entellus Medical, Inc. 2015 Incentive Award Plan. F1 · balance_after: Includes 2,500 shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Entellus Medical, Inc. 2015 Incentive Award Plan. Read SEC document |
| May 08, 2017 Filed May 8, 2017 18:02 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | PurchaseCommon Stock, $0.001 par value | 1,600 | $12.34 | $19,744.00 |
DisclosureSEC source: 0001235802-17-000050 · primary_doc.xml · nonDerivative · entry 1 Baltzell Joshua J · CIK 0001418439 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,850 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.3414 to $12.345, inclusive. The reporting person undertakes to provide to Entellus Medical, Inc., any security holder of Entellus Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 17:06 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0000899243-16-035948 · doc4.xml · derivative · entry 1 Baltzell Joshua J · CIK 0001418439 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-12-16 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 22, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.